New Haven Pharmaceuticals

About:

New Haven Pharmaceuticals develops prescription pharmaceuticals that utilize drugs or GRAS active pharmaceutical ingredients.

Website: http://www.newhavenpharma.com

Top Investors: Horizon Technology Finance, Connecticut Innovations, Advantage Capital, Yale University, Kuzari Group

Description:

New Haven Pharmaceuticals (NHP) is a specialty pharmaceuticals company developing proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications that represent significant market opportunities. The company's novel product pipeline employs proprietary, oral, controlled-release technologies, as well as intellectual property licensed from Yale University, which will enable optimal dosing, safety, efficacy and patient convenience.

Total Funding Amount:

$27.2M

Headquarters Location:

Guilford, Connecticut, United States

Founded Date:

2008-01-01

Contact Email:

pfourteau(AT)newhavenpharma.com

Founders:

Harry H. Penner

Number of Employees:

11-50

Last Funding Date:

2016-08-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai